Break-resistant
Designed to avoid the breakage risk associated with glass syringes.
Material science
Why COC instead of traditional glass?
Tungsten-free
Supports sensitive formulations without tungsten residues from glass forming.
Low protein adsorption
A high-purity polymer platform for biologics and premium therapies.
Reduced siliconization
Lower silicone requirements compared with conventional glass systems.
Design flexibility
A lightweight platform that can scale across multiple syringe volumes.
Deep-freeze readiness
The source presentation positions the platform for temperatures down to -100°C.
Market opportunity
A small market today, with high-growth potential.
$1.3B
2024 global market
$2.7B
2030 projected market
~11.6%
2024-2030 CAGR
$349M+
Accessible market for Türkiye
Figures are reproduced from the supplied investor presentation and should be independently validated before investment use.
Product portfolio
One platform, scalable product family.
SURject® Neo
0.8 mlSURject® Safe
1 mlSURject® Clear
5 mlSURject® Flex
10 mlSURject® Shield
50 mlBusiness model
One technology platform, multiple revenue paths.
OEM manufacturing
Customer-branded production and long-term supply partnerships.
CDMO services
Product, process, validation and regulatory development support.
Own SURject® products
Commercial and pipeline products from 0.8 ml to 50 ml.
International export
Target markets across Europe, MENA and Central Asia.
Investment opportunity
Building Türkiye's first COC prefilled syringe technology centre.
€1.4M
Founder investment to date
€14.9M
Investment sought for production line and commercialization
30 months
Project duration in the source cash-out plan
2033 vision
Four modular production lines, 120 million units of annual capacity and regional leadership in COC prefilled syringe manufacturing.
Access investor materials